LIFE, ACD Pen Global Distribution Pact - Analyst Blog
October 02 2013 - 5:05PM
Zacks
Life Technologies Corporation (LIFE) entered
into a global distribution agreement with Advanced Cell Diagnostics
(ACD) to commercialize the latter's fluorescent RNAscope portfolio
of probes and kits in the research market. Life Technologies will
distribute ACD's portfolio through its widespread global
distribution network.
Advanced Cell Diagnostics completed a $12 million Series B equity
financing deal in Nov 2012 to support the commercial expansion of
its unique RNAscope-based products and services in the life science
research market and expedite its entry into the clinical
diagnostics market.
The new collaboration is expected to open up a largely untapped
market and at the same time, accelerate the development of advanced
diagnostics.
On the other hand, LIFE's decision to distribute the RNAscope
portfolio reflects its long-standing commitment to make available
the most innovative products and services to the researchers. It
also marks the entry of the company into the growing tissue
analysis market. The extensive availability of the RNAscope from
ACD is expected to help researchers overcome major technical
hurdles involved in the study of the heterogeneous samples.
RNAscope technology is the first automated multiplex in situ
hybridization platform developed to detect and quantify RNA
biomarkers in situ at single-molecule sensitivity. The technology
provides single-cell gene expression information within full
cellular and tissue context. It also reveals valuable,
morphological information with respect to newly identified
biomarkers in both cells and complex tissues.
RNAscope can work with both routine clinical specimen and standard
clinical laboratory workflow. Such added features will smoothen the
work of researchers by removing the shortcomings faced due to lack
of antibodies, complementing both next-generation sequencing
(NGS) and qPCR methods.
The pioneering technology developed by ACD enables researchers to
visualize and quantify RNA in tissue samples. It can simultaneously
preserve the tissue context and provide single-molecule RNA
detection. Such improvements facilitate researchers to detect the
appropriate biomarker in specific cells, even when using a
traditional fluorescence microscope.
RNAscope is poised to become a winning technique for identifying
and validating RNA biomarkers in tissue for research, molecular
diagnostics and companion diagnostics purposes. A spontaneous rise
in discovery of biomarkers identified from microarray and NGS
technologies is anticipated due to the growing momentum of cancer
and neurobiology research.
Currently, LIFE carries a Zacks Rank #4 (Sell). Other better-placed
medical stocks that are worth a look include Trinity
Biotech plc (TRIB), carrying a Zacks Rank #1 (Strong Buy),
and Advaxis, Inc. (ADXS) and Boston
Scientific Corp. (BSX), each carrying a Zacks Rank #2
(Buy).
ADVAXIS INC (ADXS): Free Stock Analysis Report
BOSTON SCIENTIF (BSX): Free Stock Analysis Report
LIFE TECHNOLOGS (LIFE): Free Stock Analysis Report
TRINITY BIOTECH (TRIB): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
Trinity Biotech (NASDAQ:TRIB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Trinity Biotech (NASDAQ:TRIB)
Historical Stock Chart
From Apr 2023 to Apr 2024